It inhibited the expression of surface markers CD40, CD80, and MHC-II in patients with DM DCs (Figure 3A) and BMDCs (Figure 4A) but only suppressed the presence of surface marker CD80 in patients with DR DCs (Figure 5A). This evidence concerns the gene CD80 and dermatomyositis.